Preview

Современная ревматология

Расширенный поиск

Уратснижающая терапия при сердечной недостаточности

https://doi.org/10.14412/1996-7012-2019-3-109-115

Полный текст:

Аннотация

Сердечная недостаточность (СН) — одна из основных проблем общественного здравоохранения развитых стран. Гиперурикемия (ГУ) часто обнаруживается у пациентов с хронической СН (ХСН) и является известным независимым предиктором смертности и повторной госпитализации из-за прогрессирования СН. Связь ГУ с худшими клиническими исходами у пациентов с ХСН может объясняться воздействием мочевой кислоты (МК) и фермента ксантиноксидазы (КСО) на эндотелий сосудов, что ведет к высвобождению воспалительных цитокинов и активных форм кислорода. Наличие такого механизма обусловливает интерес к изучению потенциальных преимуществ ингибирования КСО у пациентов с СН. Ингибиторы КСО, вероятно, могут стать новым средством, позволяющим улучшить прогноз у этих больных.

Об авторах

О. В. Желябина
Научно-исследовательский институт ревматологии им. В.А. Насоновой
Россия

115522, Москва, Каширское шоссе, 34А.



М. С. Елисеев
Научно-исследовательский институт ревматологии им. В.А. Насоновой
Россия

Елисеев Максим Сергеевич.

115522, Москва, Каширское шоссе, 34А.



Литература

1. Liu L, Eisen HJ. Epidemiology of heart failure and scope of the problem. Cardiol Clin. 2014 Feb;32(1):1-8, vii. doi: 10.1016/j.ccl.2013.09.009.

2. Liu L. Heart Failure: Epidemiology and Research Methods. St. Louis: Elsevier Health Sciences; 2017.

3. Bui AL, Horwich TB, Fonarow GC. Epidemiology and risk profile of heart failure. Nat Rev Cardiol. 2011 Jan;8(1):30-41. doi: 10.1038/nrcardio.2010.165. Epub 2010 Nov 9.

4. Abdo AS. Hospital Management of Acute Decompensated Heart Failure. Am J Med Sci. 2017 Mar;353(3):265-274. doi: 10.1016/j.amjms.2016.08.026. Epub 2016 Sep 21.

5. Liu L. Changes in cardiovascular hospitalization and comorbidity of heart failure in the United States: findings from the National Hospital Discharge Surveys 1980-2006. Int J Cardiol. 2011 May 19;149(1):39-45. doi: 10.1016/j.ijcard.2009.11.037. Epub 2010 Jan 13.

6. Hunt SA, Abraham WT, Chin MH, et al. 2009 Focused update incorporated into the ACC/AHA 2005 guidelines for the diagnosis and management of heart failure in adults: a report of the American College of Cardiology Foundation/American Heart Association task force on practice guidelines: developed in collaboration with the International Society for Heart and Lung Transplantation. J Am Coll Cardiol. 2009 Apr 14;53(15):e1-e90. doi: 10.1016/j.jacc.2008.11.013.

7. Roger VL, Go AS, Lloyd-Jones DM, et al. American Heart Association Statistics Committee, Stroke Statistics Subcommittee. Executive summary: heart disease and stroke statistics-2012 update: a report from the American Heart Association. Circulation. 2011 Feb 1;123(4):e18-e209. doi: 10.1161/CIR.0b013e3182009701. Epub 2010 Dec 15.

8. Hamo CE, Gheorghiade M, Butler J. Novel Endpoints for Heart Failure Clinical Trials. Curr Heart Fail Rep. 2017 Aug;14(4):210-216. doi: 10.1007/s11897-017-0334-z.

9. Galassi FM, Borghi C. A brief history of uric acid: from gout to cardiovascular risk factor. Eur J Intern Med. 2015 Jun;26(5):373. doi: 10.1016/j.ejim.2015.04.005. Epub 2015 Apr 18.

10. Borghi C, Rosei EA, Bardin T, et al. Serum uric acid and the risk of cardiovascular and renal disease. JHypertens. 2015 Sep; 33(9):1729-41; discussion 1741. doi: 10.1097/HJH.0000000000000701.

11. Landolfo M, Borghi C. Hyperuricaemia and vascular risk: the debate continues. Curr Opin Cardiol. 2019 Jul;34(4):399-405. doi: 10.1097/HC0.0000000000000626.

12. Tao M, Pi X, Ma X, et al. Relationship between serum uric acid and clustering of cardiovascular disease risk factors and renal disorders among Shanghai population: a multicentre and cross-sectional study. BMJ Open. 2019 Mar 1;9(3):e025453. doi: 10.1136/bmjopen-2018-025453.

13. Zhou HB, Xu TY, Liu SR, et al. Association of serum uric acid change with mortality, renal function and diuretic dose administered in treatment of acute heart failure. Nutr Metab Cardiovasc Dis. 2019 Apr; 29(4):351-359. doi: 10.1016/j.numecd.2019.01.001. Epub 2019 Jan 12.

14. Krishnan E. Gout and the risk for inci-dent heart failure and systolic dysfunction. BMJ Open. 2012 Feb 15;2(1):e000282. doi: 10.1136/bmjopen-2011-000282. Print 2012.

15. Borghi C, Desideri G. Urate-lowering drugs and prevention of cardiovascular disease: the emerging role of xanthine oxidase inhibition. Hypertension. 2016 Mar;67(3): 496-8. doi: 10.1161/HYPERTENSIONA-HA.115.06531. Epub 2016 Jan 25.

16. Huang H, Huang B, Li Y, et al. Uric acid and risk of heart failure: a systematic review and meta-analysis. Eur J Heart Fail. 2014 Jan;16(1):15-24. doi: 10.1093/eurjhf/hft132. Epub 2013 Dec 3.

17. Strasak A, Ruttmann E, Brant L, et al; VHM&PP Study Group. Serum uric acid and risk of cardiovascular mortality: a prospective long-term study of 83,683 Austrian men. Clin Chem. 2008 Feb;54(2):273-84. Epub 2007 Nov 26. DOI: 10.1373/clinchem.2007.094425

18. Strasak AM, Kelleher CC, Brant LJ, et al; VHM&PP Study Group. Serum uric acid is an independent predictor for all major forms of cardiovascular death in 28,613 elderly women: a prospective 21-year follow-up study. Int J Cardiol. 2008 Apr 10;125(2): 232-9. doi: 10.1016/j.ijcard.2007.11.094. Epub 2008 Jan 30.

19. Chen JH, Chuang SY, Chen HJ, et al. Serum uric acid level as an independent risk factor for all-cause, cardiovascular, and ischemic stroke mortality: a Chinese cohort study. Arthritis Rheum. 2009 Feb 15;61(2): 225-32. doi: 10.1002/art.24164.

20. Bendall JK, Cave AC, Heymes C, et al. Pivotal role of a gp91(phox)-containing NADPH oxidase in angiotensin II-induced cardiac hypertrophy in mice. Circulation. 2002 Jan 22;105(3):293-6. doi: 10.1161/hc0302.103712.

21. Prasad K, Kalra J, Chan WP, et al. Effect of oxygen free radicals on cardiovascular function at organ and cellular levels. Am Heart J. 1989 Jun;117(6):1196-202. doi: 10.1016/0002-8703(89)90396-7.

22. Hess ML, Okabe E, Kontos HA. Proton and free oxygen radical interaction with the calcium transport system of cardiac sarcoplasmatic reticulum. J Mol Cell Cardiol. 1981 Aug;13(8):767-72.

23. Freeman BA, Crapo JD. Biology of disease: free radicals and tissue injury. Lab Invest. 1982 Nov;47(5):412-26.

24. Меерзон ФЗ, Каган ВЕ, Козлов ЮП и др. Роль перекисного окисления липидов в патогенезе ишемического повреждения и антиоксидантная защита сердца. Кардиология. 1982;22(2):81-93.

25. Khan SA, Lee K, Minhas KM, et al. Neuronal nitric oxide synthase negatively regulates xanthine oxidoreductase inhibition of cardiac excitation-contraction coupling. Proc Natl Acad Sci US A. 2004 Nov 9;101(45): 15944-8. Epub 2004 Oct 14. doi: 10.1073/pnas.0404136101.

26. Lee CI, Liu X, Zweier JL. Regulation of xanthine oxidase by nitric oxide and peroxynitrite. JBiol Chem. 2000 Mar 31;275(13): 9369-76. doi: 10.1074/jbc.275.13.9369.

27. Maxwell AJ, Bruinsma KA. Uric acid is closely linked to vascular nitric oxide activity. Evidence for mechanism of association with cardiovascular disease. Am Coll Cardiol. 2001 Dec;38(7):1850-8.

28. Roch-Ramel F, Guisan B, Diezi J. Effects of uricosuric and antiuricosuric agents on urate transport in human brush-border membrane vesicles. J Pharmacol Exp Ther. 1997 Feb;280(2):839-45.

29. Anker SD, Coats AJ. Metabolic, functional, and haemodynamic staging for CHF. Lancet. 1996 Dec 7;348(9041):1530-1. doi: 10.1016/S0140-6736(05)66163-6.

30. Anker SD, Doehner W, Rauchhaus M, et al. Uric acid and survival in chronic heart failure. Validation and application in meta-bolic, functional and hemodynamic staging. Circulation. 2003 Apr 22;107(15):1991-7. Epub 2003 Apr 21. doi: 10.1161/01.CIR.0000065637.10517.A0.

31. Okazaki H, Shirakabe A, Matsushita M, et al. Plasma xanthine oxidoreductase activity in patients with decompensated acute heart failure requiring intensive care. ESC Heart Fail. 2019 Apr;6(2):336-343. doi: 10.1002/ehf2.12390. Epub 2019 Jan 8.

32. Mackenzie IS, Ford I, Walker A, et al; ALL-HEART study group. A multicentre, prospective, randomised, open-label, blinded endpoint trial of the efficacy of allopurinol therapy in improving cardiovascular outcomes in patients with ischaemic heart disease: protocol of the ALLHEART study. BMJ Open. 2016 Sep 8;6(9):e013774. doi: 10.1136/bmjopen-2016-013774.

33. Johnson RJ, Kang DH, Feig D, et al. Is there a pathogenetic role for uric acid in hypertension and cardiovascular and renal disease? Hypertension. 2003 Jun;41(6): 1183-90. Epub 2003 Apr 21. doi: 10.1161/01.HYP.0000069700.62727.C5.

34. Bergamini C, Cicoira M, Rossi A, Vassanelli C. Oxidative stress and hyperuricaemia: pathophysiology, clinical relevance, and therapeutic implications in chronic heart failure. Eur J Heart Fail. 2009 May;11(5): 444-52. doi: 10.1093/eurjhf/hfp042. Epub 2009 Apr 4. doi: 10.1093/eurjhf/hfp042

35. Hayashi K, Kimata H, Obata K, et al. Xanthine oxidase inhibition improves left ventricular dysfunction in dilated cardiomyopathic hamsters. J Card Fail. 2008 Apr;14(3):238-44. doi: 10.1016/j.cardfail.2007.11.001.

36. Minhas KM, Saraiva RM, Schuleri KH, et al. Xanthine oxidoreductase inhibition causes reverse remodeling in rats with dilated cardiomyopathy. Circ Res. 2006 Feb 3;98(2): 271-9. Epub 2005 Dec 15. doi: 10.1161/01.RES.0000200181.59551.71.

37. George J, Carr E, Davies J, et al. High-dose allopurinol improves endothelial function by profoundly reducing vascular oxidative stress and not by lowering uric acid. Circulation. 2006 Dec 5;114(23):2508-16. Epub 2006 Nov 27. doi: 10.1161/CIRCULATIONAHA.106.651117].

38. Pavlusova M, Jarkovsky J, Benesova K, et al. Treatment in acute heart failure patients does not improve their long-term prognosis: A propensity score matched analysis from the AHEAD registry. Clin Cardiol. 2019 May 22. doi: 10.1002/clc.23197. [Epub ahead of print].

39. Cicero AFG, Cosentino ER, Kuwabara M, et al. Effects of allopurinol and febuxostat on cardiovascular mortality in elderly heart failure patients. Intern Emerg Med. 2019 Mar 12. doi: 10.1007/s11739-019-02070-y. [Epub ahead of print].

40. Zhang Z, Blake DR, Stevens CR, et al. A reappraisal of xanthine dehydrogenase and oxidase in hypoxic reperfusion injury: the role of NADH as an electron donor. Free Radic Res. 1998 Feb;28(2):151-64.

41. Pea F. Pharmacology of drugs for hyperuricemia: mechanisms, kinetics and interactions. Contrib Nephrol. 2005;147:35-46. doi: 10.1159/000082540.

42. Borghi C, Perez-Ruiz F. Urate lowering therapies in the treatment of gout: a systematic review and metaanalysis. Eur Rev Med Pharmacol Sci. 2016 Mar;20(5):983-92.

43. Sarvepalli PS, Fatima M, Quadri AK, et al. Study of therapeutic efficacy of febuxostat in chronic kidney disease stage IIIA to stage VD. Saudi J Kidney Dis Transpl. 2018 Sep-Oct;29(5):1050-1056. doi: 10.4103/1319-2442.243953.

44. Tuegel C, Bansal N. Heart failure in patients with kidney disease. Heart. 2017 Dec;103(23):1848-1853. doi: 10.1136/heartjnl-2016-310794. Epub 2017 Jul 17.

45. Foody J, Turpin RS, Tidwell BA, et al. Major Cardiovascular Events in Patients with Gout and Associated Cardiovascular Disease or Heart Failure and Chronic Kidney Disease Initiating a Xanthine Oxidase Inhibitor. Am Health Drug Benefits. 2017 Nov;10(8): 393-401.

46. Mitri G, Wittbrodt ET, Turpin RS, et al. Cost Comparison of Urate-Lowering Therapies in Patients with Gout and Moderate-to-Severe Chronic Kidney Disease. Manag Care Spec Pharm. 2016 Apr;22(4):326-36. doi: 10.18553/jmcp.2016.22.4.326.

47. Fukui T, Maruyama M, Yamauchi K, et al. Effects of Febuxostat on Oxidative Stress. Clin Ther. 2015 Jul 1;37(7):1396-401. doi: 10.1016/j.clinthera.2015.03.026. Epub 2015 Apr 23.

48. Rablink TJ, Luscher TF. Endothelial nitric oxide synthase: host defense enzyme of the endothelium? Arterioscler Thromb Vasc Biol. 2006 Feb;26(2):267-71. Epub 2005 Nov 17. doi: 10.1161/01.ATV.0000196554.85799.77.

49. White WB, Saag KG, Becker MA, et al. Cardiovascular Safety of Febuxostat or Allopurinol in Patients with Gout. N Engl J Med. 2018 Mar 29;378(13):1200-1210. doi: 10.1056/NEJMoa1710895. Epub 2018 Mar 12.

50. Becker MA, Schumacher HR, MacDonald PA, et al. Clinical efficacy and safety of successful longterm urate lowering with febuxostat or allopurinol in subjects with gout. J Rheumatol. 2009 Jun;36(6):1273-82. doi: 10.3899/jrheum.080814. Epub 2009 Mar 13.

51. Schumacher HR Jr, Becker MA, Wortmann RL, et al. Effects of febuxostat versus allopurinol and placebo in reducing serum urate in subjects with hyperuricemia and gout: a 28-week, phase III, randomized, double-blind, parallel-group trial. Arthritis Rheum. 2008 Nov 15;59(11):1540-8. doi: 10.1002/art.24209.

52. Becker MA, Schumacher HR Jr, Wortmann RL, et al. Febuxostat, a novel nonpurine selective inhibitor of xanthine oxidase: a twenty-eight-day, multicenter, phase II, randomized, double-blind, placebo-controlled, dose-response clinical trial examining safety and efficacy in patients with gout. Arthritis Rheum. 2005 Mar;52(3):916-23. Arthritis Rheum. 2008 Nov 15;59(11):1540-8. doi: 10.1002/art.24209.

53. Schumacher HR Jr, Becker MA, Lloyd E, et al. Febuxostat in the treatment of gout: 5-yr findings of the FOCUS efficacy and safety study. Rheumatology (Oxford). 2009 Feb; 48(2):188-94. doi: 10.1093/rheumatology/ken457.

54. Choi H, Neogi T, Stamp L, et al. Implications of the cardiovascular safety of febuxostat and allopurinol in patients with gout and cardiovascular morbidities (CARES) trial and associated FDA public safety alert. Arthritis Rheumatol. 2018 Nov;70(11):1 702-1709. doi: 10.1002/art.40583.

55. Елисеев МС. Сердечно-сосудистая безопасность фебуксостата. Анализ исследования CARES. Современная ревматология. 2018;12(4):42-6. doi: 10.14412/1996-7012-2018-4-42-46.

56. Zhang M, Solomon DH, Desai RJ, et al. Assessment of Cardiovascular Risk in Older Patients With Gout Initiating Febuxostat Versus Allopurinol. Circulation. 2018 Sep 11; 138(11):1116-1126. doi: 10.1161/CIRCULATIONAHA.118.033992.

57. Kojima S, Matsui K, Hiramitsu S, et al. Febuxostat for Cerebral and CaRdiorenovascular Events PrEvEntion StuDy. EurHeart J. 2019 Jun 7;40(22):1778- 1786. doi: 10.1093/eurheartj/ehz119.

58. Moriarity JT, Folsom AR, Iribarren C, et al. Serum uric acid and risk of coronary heart disease: Atherosclerosis Risk in Communities (ARIC) Study, nn Epidemiol. 2000 Apr;10(3):136-43.

59. Baek CH, Kim H, Yang WS, et al. Efficacy and Safety of Febuxostat in Kidney Transplant Patients. Exp Clin Transplant. 2018 Aug;16(4):401-406. doi: 10.6002/ect.2016.0367. Epub 2017 Dec 18.

60. Chou HW, Chiu HT, Tsai CW, et al. Comparative effectiveness of allopurinol, febuxostat and benzbromarone on renal function in chronic kidney disease patients with hyperuricemia: a 13-year inception cohort study. Nephrol Dial Transplant. 2018 Sep 1; 33(9):1620-1627. doi: 10.1093/ndt/gfx313.

61. Juge PA, Truchetet ME, Pillebout E, et al. Efficacy and safety of febuxostat in 73 gouty patients with stage 4/5 chronic kidney disease: A retrospective study of 10 centers. Joint Bone Spine. 2017 Oct;84(5):595-598. doi: 10.1016/jjbspin.2016.09.020. Epub 2016 Nov 4.


Для цитирования:


Желябина О.В., Елисеев М.С. Уратснижающая терапия при сердечной недостаточности. Современная ревматология. 2019;13(3):109-115. https://doi.org/10.14412/1996-7012-2019-3-109-115

For citation:


Zhelyabina O.V., Eliseev M.S. Urate-lowering therapy for heart failure. Modern Rheumatology Journal. 2019;13(3):109-115. (In Russ.) https://doi.org/10.14412/1996-7012-2019-3-109-115

Просмотров: 51


Creative Commons License
Контент доступен под лицензией Creative Commons Attribution 4.0 License.


ISSN 1996-7012 (Print)
ISSN 2310-158X (Online)